Status:
COMPLETED
A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Non-small-cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to characterize the safety profile of ZD1839 in combination with Palliative thoracic Radiotherapy in patients with non-small cell lung cancer
Eligibility Criteria
Inclusion
- Provision of written informed consent
- Patients requiring low dose palliative thoracic irradiation to a field size of less than or equal to 150cm2
- Histologically or cytologically conformed non-small cell lung cancer
- Aged 18 or over
Exclusion
- Previous thoracic radiotherapy
- Any condition that may pre-dispose the patient to suffer an individual drug-relaged DLT (dose limiting toxicity) event
- Known hypersensitivity to any component of study medication
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
End Date :
June 1 2006
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00255489
Start Date
May 1 2004
End Date
June 1 2006
Last Update
January 25 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Edinburgh, United Kingdom
2
Research Site
Leeds, United Kingdom